Viekira on blockbuster pace as AbbVie adds 2nd HCV drug
This article was originally published in Scrip
Viekira Pak, AbbVie's fixed-dose combination therapy for hepatitis C, fell short of Wall Street consensus sales estimates during the second quarter, but the Chicago-area pharma company pointed to several factors causing below-expectation US sales, while international sales exceeded projections.
You may also be interested in...
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.